- 1				
1	WHEREAS, Verinata Health, Inc. and Illumina Inc. (collectively, "Plaintiffs") asserted			
2	claims of infringement of U.S. Patent Nos. 7,955,794 and 8,318,430 (collectively, "Patents-in-			
3	Suit") against Ariosa Diagnostics, Inc. and Roche Molecular Systems, Inc. (collectively,			
4	"Defendants") (Dkt. No. 349 (Civ. A. No. 12-cv-05501-SI); Dkt. No. 1 (Civ. A. No. 14-cv-01921-			
5	SI); Dkt. No. 17 (Civ. A. No. 15-cv-02216-SI));			
6	WHEREAS, Defendants asserted affirmative defenses, counterclaims for non-infringement			
7	and invalidity of the Patents-in-Suit, and counterclaims for breach of contract and breach of the			
8	covenant of good faith and fair dealing, against Plaintiffs (Dkt. No. 352 (Civ. A. No. 12-cv-05501-			
9	SI); Dkt. No. 102-1 (Civ. A. No. 14-cv-01921-SI));			
10	WHEREAS, this Court entered its Judgment on January 29, 2018 (Dkt. No. 642), and Order			
11	re Post-Trial Motions on July 19, 2018 (Dkt. No. 705), as modified by the Order re Clarification on			
12	October 4, 2018 (Dkt. No. 721) (collectively, "Judgment"));			
13	WHEREAS, the United States Court of Appeals for the Federal Circuit issued its Opinion			
14	and Judgment on April 24, 2020 (Dkt. Nos. 729 & 730), and issued its formal mandate on August			
15	14, 2020 (Dkt. No. 736), wherein it affirmed this Court's Judgment;			
16	WHEREAS, Plaintiffs have pending motions for supplemental pre-verdict and post-verdict			
17	royalties (Dkt. Nos. 742, 743-4); and			
18	WHEREAS, Plaintiffs and Defendants have mutually agreed to a settlement of Plaintiffs'			
19	and Defendants' respective claims;			
20	NOW, THEREFORE, IT IS HEREBY STIPULATED AND AGREED, by and between			
21	Plaintiffs and Defendants, through their respective undersigned counsel, subject to the approval of			
22	the Court, that			
23	1. The Court's Judgment against Defendants is deemed satisfied.			
24	2. Plaintiffs' pending motions for supplemental pre-verdict and post-verdict royalties			
25	(Dkt. Nos. 742, 743-4) are withdrawn with prejudice.			
26	3. Each party shall bear its own costs, expenses, and attorneys' fees incurred with			

27

respect to all claims, defenses, and counterclaims in this Action.

1		Respectfully submitted,		
2		WEII	L, GOTSHAL & MANGES LLP	
3	Dated: May 26, 2021	By:	/s/ Edward R. Reines	
4	,,	_ ;	Edward R. Reines	
5			Edward R. Reines (Bar No. 135960) edward.reines@weil.com	
6			WEIL, GOTSHAL & MANGES LLP 201 Redwood Shores Parkway Redwood Shores, CA 94065	
7			Telephone: (650) 802-3000 Facsimile: (650) 802-3100	
8			. ,	
9			Attorney for Plaintiffs/Counterclaim- Defendants	
10			VĚRINATA HEALTH, INC. and ILLUMINA, INC.	
11				
12				
13		IREL	L & MANELLA LLP	
14		By:	/s/ Lisa S. Glasser	
15	Dated: May 26, 2021	Dy.	Lisa S. Glasser	
16			Lisa S. Glasser (Bar No. 223406)	
17			lglasser@irell.com 840 Newport Center Drive, Suite 400	
18			Newport Beach, CA 92660-6324 Telephone: (949) 760-0991	
19			Facsimile: (949) 760-5200	
20			Attorney for Defendant/Counterclaim- Plaintiff	
21			ARIOSA DIAGNOSTICS, INC.	
22				
23	<u>CERTIFICATION</u>			
24	I, Edward R. Reines, am the ECF User whose identification and password are being used to			
25	file this Joint Stipulation Of Dismissal With Prejudice and [Proposed] Order. In compliance with			
26	Civil Local Rule 5-1(i)(3), I hereby attest that Lisa S. Glasser has concurred in this filing.			
27				
28		Ľuv	ard K. Kellies	
	JOINT STIPULATION OF DISMISSAL	2	CASE No. 3:12-CV-05501-SI	

SO ORDERED this 27th day of May 2021.

HONORABLE SUSAN Y. ILLSTON UNITED STATES DISTRICT JUDGE